Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 6/20 | 0.45 |
| ▸ | PDE9A | O76083 | 3/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424564 | 0.87 | CLPP (0.49) | CLPPPDE9AFABP4 | |
| SCHEMBL22424223 | 0.87 | CLPP (0.49) | CLPPPDE9AFABP4 | |
| SCHEMBL22424344 | 0.87 | CLPP (0.49) | CLPPPDE9AFABP4 | |
| SCHEMBL22424333 | 0.80 | CLPP (0.54) | CLPPPDE9A | |
| SCHEMBL22424585 | 0.76 | CLPP (0.52) | CLPPPDE9A | |
| SCHEMBL22424550 | 0.74 | CLPP (0.53) | CLPPPDE9AMEN1KMT2A | |
| SCHEMBL22424217 | 0.73 | CLPP (0.52) | CLPPPDE9A | |
| SCHEMBL22424384 | 0.72 | CLPP (0.51) | CLPPPDE9A | |
| SCHEMBL22424574 | 0.72 | CLPP (0.51) | CLPPPDE9A | |
| SCHEMBL22423998 | 0.69 | CLPP (0.60) | CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |